Principal Investigators

    Professor Kumlesh K. Dev


    Trinity College Dublin

    Contact information of lead PI



    Title of project or programme

    Examining the effects of S1P receptor drugs in Alzheimer’s disease

    Source of funding information

    Health Research Board

    Total sum awarded (Euro)

    € 299,810

    Start date of award


    Total duration of award in years



    Research Abstract

    Alzheimer’s disease (AD) is set to affect 1 in every 3 people as the global demographics age. To date, however, treatments against AD are limited and if left untreated AD will likely have unmanageable implications on healthcare, financial and societal systems. Sphingosine 1-phosphate receptors (S1PRs) are composed of subtypes S1PR1-5 and are expressed on many cells types including those of the immune, cardiovascular and central nervous systems. S1PRs are targets for the drug fingolimod, which is the first oral therapy recently approved for use in patients with multiple sclerosis (MS). The phosphorylated version of fingolimod (pFTY720) binds to all S1PRs, except S1PR2. Studies have shown pFTY720 internalises S1P1Rs on T cells limiting their egress from lymph nodes and limiting inflammatory response in MS. Importantly, pFTY720 also binds to S1PRs on neuronal and glial cells and is thought regulate neuronal and glial cell survival, proliferation, differentiation, migration and function. Recently, the S1PR modulator fingolimod (pFTY720) has been shown to be beneficial in animal models of AD. We hypothesise that the protective effects of pFTY720 in animal models of AD are likely mediated through its effects on both immune and neuronal/glial cells, with the S1PR1 and S1PR5 subtypes playing a major role. Given that pFTY720 is a pan-S1PR modulator, here we aim to demonstrate if selective S1PR1 and S1PR5 compounds mediate protective effects in animal models of AD. This work will (i) corroborate previous findings for use of S1PR drugs in AD and (ii) clarify the S1PR profile required for a drug to be use in AD. Both these findings will be pivotal in designing and implementing a clinical trial that tests the use of S1PR drugs in AD.

    Further information available at:

Types: Investments < €500k
Member States: Ireland
Diseases: N/A
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF